• Explore /
  • Poster
  • / An open-label, multicenter, phase 1 study of RP3 as a single agent and in combination with nivolumab in patients (pts) with solid tumors.

An open-label, multicenter, phase 1 study of RP3 as a single agent and in combination with nivolumab in patients (pts) with solid tumors.

Abstract Poster

Authors

null

Kevin Joseph Harrington

The Royal Marsden//The Institute of Cancer Research NIHR Biomedical Research Centre, London, United Kingdom

Kevin Joseph Harrington , Antonio Rullan , Louise Deighton , Joao Barata , Henry Castro , Christoph Matthias Ahlers , John McRae , Praveen Bommareddy , Robert S. Coffin , Mark R. Middleton

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Other IO-Related Topics

Clinical Trial Registration Number

NCT04735978

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS2705)

DOI

10.1200/JCO.2022.40.16_suppl.TPS2705

Abstract #

TPS2705

Poster Bd #

340a

Abstract Disclosures

Similar Posters

First Author: Kevin Joseph Harrington

First Author: Mark R. Middleton

First Author: Filip Janku

First Author: Lakshmi Rajdev